METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg
APHP211003
Phase 3 small_molecule active
Quick answer
METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg for Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active